|
|
| | CTCE 9908 Basic information |
| Product Name: | CTCE 9908 | | Synonyms: | CTCE 9908;L-Lysinamide, N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-;N2,N6-Bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-L-lysinamide;CTCE 9908 TFA;PTX-9908 | | CAS: | 1030384-98-5 | | MF: | C86H147N27O23 | | MW: | 1927.25 | | EINECS: | | | Product Categories: | | | Mol File: | 1030384-98-5.mol |  |
| | CTCE 9908 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | | form | Powder | | color | White to off-white |
| | CTCE 9908 Usage And Synthesis |
| Uses | CXCR4 is a chemokine receptor often overexpressed in cancer cells and involved with metastasis. N2,N6-Bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-L-lysinamide is a CXCR4 antagonist. It inhibits ovarian cancer cell migration to CXCL12 and induces cell death in CXCR4-positive cells. | | in vivo | CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg in FVB/N TgN (MMTV-PyMT)634 male mice[2].
| | IC 50 | CXCR4 | | storage | Store at -20°C |
| | CTCE 9908 Preparation Products And Raw materials |
|